IP Library › Granted Patent US 10,570,468
Granted Patent B2
US 10,570,468 · App. 16/275,734 · Granted Feb 25, 2020

Crystallized oxalate decarboxylase and methods of use

Inventors: Jack Greene (Allston, MA); Richard Johnson (West Bridgford, GB); Dennis Krushinskie (South Grafton, MA); Bhami Shenoy (South Grafton, MA)
Assignee: Allena Pharmaceuticals, Inc.
C12Y401/01002A61K9/1623A61K9/1635A61K9/1647A61K9/1652A61K38/51C12N9/88A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,468
App. No.
16/275,734
Granted
Feb 25, 2020
Kind
B2
Abstract

Pharmaceutical compositions comprising spray-dried oxalate decarboxylase crystals are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using compositions comprising spray-dried oxalate decarboxylase crystals are also disclosed.

Claims (15)

1. A method of reducing oxalate concentration in the plasma of a subject, the method comprising administering to the subject at least one capsule comprising crystals of spray-dried oxalate decarboxylase comprising the amino acid sequence of SEQ ID NO:1, wherein the thiol moiety at Cys383 is protected by a thiol protecting group, and wherein the crystals have a Hausner ratio of about 1.00 to about 1.59, thereby to reduce oxalate concentration in the plasma of the subject.

2. The method of claim 1 , wherein the capsule further comprises an excipient.

3. The method of claim 2 , wherein the excipient is a sugar.

4. The method of claim 3 , wherein the sugar is a disaccharide or a monosaccharide.

5. The method of claim 4 , wherein the sugar is selected from trehalose, sucrose, and glucose.

6. The method of claim 5 , wherein the sugar is trehalose.

7. The method of claim 1 , wherein the crystals have a Hausner ratio of about 1.00 to about 1.34.

8. The method of claim 7 , wherein the crystals have a Hausner ratio of about 1.00 to about 1.25.

9. The method of claim 8 , wherein the crystals have a Hausner ratio of about 1.00 to about 1.18.

10. The method of claim 9 , wherein the crystals have a Hausner ratio of about 1.12 to about 1.18.

11. The method of claim 8 , wherein the crystals have a Hausner ratio of about 1.19 to about 1.25.

12. The method of claim 7 , wherein the crystals have a Hausner ratio of about 1.26 to about 1.34.

13. The method of claim 1 , wherein the crystals have a Hausner ratio of about 1.34.

14. The method of claim 1 , wherein the capsule comprises at least 5,000 U of oxalate decarboxylase crystals.

15. The method of claim 1 , wherein the capsule comprises at least 3,000 U of oxalate decarboxylase crystals.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: ALLENA PHARMACEUTICALS
To: GLYSCEND, INC.
Reel/Frame 065554/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2019
From: GREENE, JACK; JOHNSON, RICHARD; KRUSHINSKIE, DENNIS; SHENOY, BHAMI
To: ALLENA PHARMACEUTICALS, INC.
Reel/Frame 050664/0706 →
Continuity (4)
Continuation 15630978 · Jun 23, 2017
Continuation 14761521
Provisional Application 61754342 · Jan 18, 2013
Related Publication 20200024673A1 · Jan 23, 2020